KR20060123295A - 경피흡수형 뇌 보호제 - Google Patents
경피흡수형 뇌 보호제 Download PDFInfo
- Publication number
- KR20060123295A KR20060123295A KR1020067011405A KR20067011405A KR20060123295A KR 20060123295 A KR20060123295 A KR 20060123295A KR 1020067011405 A KR1020067011405 A KR 1020067011405A KR 20067011405 A KR20067011405 A KR 20067011405A KR 20060123295 A KR20060123295 A KR 20060123295A
- Authority
- KR
- South Korea
- Prior art keywords
- mass
- base
- brain
- rubber
- methyl
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
군 | 동물 수 | 뇌경색 면적(㎟) | ||||
Bregma+4 | Bregma+2 | Bregma | Bregma-2 | Bregma-4 | ||
시험군 | 12 | 2.2±0.7 | 14.3±2.1 | 28.3±3.1 | 27.8±3.5 | 30.4±3.4* |
대조군 | 12 | 4.8±1.3 | 21.0±2.9 | 34.6±3.0 | 37.4±3.5 | 19.0±3.8 |
Claims (15)
- 제1항에 있어서,상기 기제가 수성 기제인 것을 특징으로 하는 경피흡수형 뇌 보호제.
- 제2항에 있어서,상기 수성 기제가 상기 수성 기제의 총량에 기초하여, 수용성 고분자 1∼20 질량%, 가교제 0.01∼20 질량%, 다가 알코올 10∼80 질량% 및 물 1∼80 질량%를 함유하는 것을 특징으로 하는 경피흡수형 뇌 보호제.
- 제1항에 있어서,상기 기제가 고무계 기제인 것을 특징으로 하는 경피흡수형 뇌 보호제.
- 제4항에 있어서,상기 고무계 기제가 상기 고무계 기제의 총량에 기초하여, 고무계 고분자 10∼50 질량%, 가소제 10∼50 질량% 및 점착부여제 5∼50 질량%를 함유하는 것을 특징으로 하는 경피흡수형 뇌 보호제.
- 제6항에 있어서,상기 기제가 수성 기제인 것을 특징으로 하는 염을 사용하는 방법.
- 제7항에 있어서,상기 수성 기제가, 상기 수성 기제의 총량에 기초하여, 수용성 고분자 1∼20 질량%, 가교제 0.01∼20 질량%, 다가 알코올 10∼80 질량% 및 물 1∼80 질량%를 함유하는 것을 특징으로 하는 염을 사용하는 방법.
- 제6항에 있어서,상기 기제가 고무계 기제인 것을 특징으로 하는 염을 사용하는 방법.
- 제9항에 있어서,상기 고무계 기제가 상기 고무계 기제의 총량에 기초하여, 고무계 고분자 10∼50 질량%, 가소제 10∼50 질량% 및 점착부여제 5∼50 질량%를 함유하는 것을 특징으로 하는 염을 사용하는 방법.
- 제11항에 있어서,상기 기제가 수성 기제인 것을 특징으로 하는 뇌의 보호방법.
- 제12항에 있어서,상기 수성 기제가, 상기 수성 기제의 총량에 기초하여, 수용성 고분자 1∼20 질량%, 가교제 0.01∼20 질량%, 다가 알코올 10∼80 질량% 및 물 1∼80 질량%를 함유하는 것을 특징으로 하는 뇌의 보호방법.
- 제11항에 있어서,상기 기제가 고무계 기제인 것을 특징으로 하는 뇌의 보호방법.
- 제14항에 있어서,상기 고무계 기제가 상기 고무계 기제의 총량에 기초하여, 고무계 고분자 10∼50 질량%, 가소제 10∼50 질량% 및 점착부여제 5∼50 질량%를 함유하는 것을 특징으로 하는 뇌의 보호방법.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/014362 WO2005046680A1 (ja) | 2003-11-12 | 2003-11-12 | 経皮吸収型脳保護剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060123295A true KR20060123295A (ko) | 2006-12-01 |
KR101008052B1 KR101008052B1 (ko) | 2011-01-13 |
Family
ID=34587050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067011405A KR101008052B1 (ko) | 2003-11-12 | 2003-11-12 | 경피흡수형 뇌 보호제 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8076368B2 (ko) |
EP (1) | EP1685837A4 (ko) |
JP (1) | JP5131578B2 (ko) |
KR (1) | KR101008052B1 (ko) |
CN (1) | CN100528153C (ko) |
AU (1) | AU2003280739A1 (ko) |
CA (1) | CA2546064C (ko) |
WO (1) | WO2005046680A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009041714A1 (ja) * | 2007-09-26 | 2011-01-27 | 三笠製薬株式会社 | フリーラジカル性疾患用外用剤 |
CN101524352A (zh) | 2008-03-04 | 2009-09-09 | 江苏先声药物研究有限公司 | 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物 |
KR101855549B1 (ko) * | 2011-02-02 | 2018-05-04 | 닛토덴코 가부시키가이샤 | 첩부 제제 |
WO2015020153A1 (ja) * | 2013-08-09 | 2015-02-12 | 帝國製薬株式会社 | ベラプロスト含有貼付剤 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK169672B1 (da) * | 1985-05-20 | 1995-01-09 | Mitsubishi Chem Ind | Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater |
JPS62108814A (ja) | 1985-11-07 | 1987-05-20 | Mitsubishi Chem Ind Ltd | 過酸化脂質生成抑制剤 |
JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
JPH066533B2 (ja) * | 1985-09-13 | 1994-01-26 | 日東電工株式会社 | 含水ゲル貼付剤の基剤 |
JPH078784B2 (ja) * | 1987-02-20 | 1995-02-01 | 久光製薬株式会社 | 親水性経皮投与製剤 |
JP2512565B2 (ja) * | 1989-10-13 | 1996-07-03 | 積水化学工業株式会社 | 貼付剤 |
JP2906512B2 (ja) | 1990-01-16 | 1999-06-21 | 三菱化学株式会社 | 抗潰瘍剤 |
JP2906513B2 (ja) | 1990-01-16 | 1999-06-21 | 三菱化学株式会社 | 血糖上昇抑制剤 |
JP2569396B2 (ja) * | 1992-12-04 | 1997-01-08 | 株式会社太平洋 | 経皮投与型薬物用貼付剤 |
JPH0748250A (ja) | 1993-06-04 | 1995-02-21 | Sekisui Chem Co Ltd | 眠気防止用テープ |
JPH0725765A (ja) | 1993-07-07 | 1995-01-27 | Mitsubishi Chem Corp | 眼疾患用薬剤 |
WO1996029062A1 (fr) * | 1995-03-22 | 1996-09-26 | Teikoku Seiyaku Kabushiki Kaisha | Feuille produisant du froid |
JPH0912448A (ja) | 1995-04-28 | 1997-01-14 | Read Chem Kk | 薬物放出制御型経皮吸収製剤 |
JPH0952831A (ja) | 1995-08-10 | 1997-02-25 | Mitsubishi Chem Corp | 急性腎不全治療・予防剤 |
ATE222759T1 (de) * | 1996-02-07 | 2002-09-15 | Lead Chem Co Ltd | Tranilast enthaltendes externum und verfahren zu dessen herstellung |
JPH10120560A (ja) | 1996-08-26 | 1998-05-12 | Sankyo Co Ltd | ロキソプロフェン含有外用製剤 |
AU4321297A (en) * | 1996-10-04 | 1998-04-24 | Saitama Daiichi Seiyaku Kabushiki Kaisha | Patch |
JPH10265373A (ja) * | 1997-03-26 | 1998-10-06 | Lion Corp | 粘着剤組成物及びパップ剤 |
JPH10279480A (ja) * | 1997-04-07 | 1998-10-20 | Mitsubishi Chem Corp | 皮膚組織障害の予防・治療剤 |
KR100238180B1 (ko) * | 1997-05-02 | 2000-01-15 | 윤종용 | 제어 윈도우를 이용한 컴퓨터 통신용 제어 방법 |
US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
JP3943724B2 (ja) * | 1998-07-31 | 2007-07-11 | 東光薬品工業株式会社 | フェンタニル含有経皮投与マトリックス型貼付剤 |
WO2000064434A1 (fr) | 1999-04-26 | 2000-11-02 | Lead Chemical Co., Ltd. | Preparations percutanees contenant de l'oxybutynine |
EP1405637B1 (en) * | 2000-10-24 | 2005-09-07 | Mitsubishi Pharma Corporation | Remedies for amyotrophic lateral sclerosis (als) |
WO2003024446A1 (fr) * | 2001-09-11 | 2003-03-27 | Mitsubishi Pharma Corporation | Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif |
JP4372398B2 (ja) * | 2002-09-06 | 2009-11-25 | 三笠製薬株式会社 | フリーラジカル性疾患用外用剤 |
WO2004041270A1 (ja) * | 2002-11-05 | 2004-05-21 | Lead Chemical Co.,Ltd. | 3−メチル−1−フェニル−2−ピラゾリン−5−オン含有経皮吸収製剤 |
JP2004307364A (ja) * | 2003-04-03 | 2004-11-04 | Yuutoku Yakuhin Kogyo Kk | 経皮吸収貼付剤 |
-
2003
- 2003-11-12 EP EP03772698A patent/EP1685837A4/en not_active Withdrawn
- 2003-11-12 AU AU2003280739A patent/AU2003280739A1/en not_active Abandoned
- 2003-11-12 CA CA2546064A patent/CA2546064C/en not_active Expired - Lifetime
- 2003-11-12 US US10/579,055 patent/US8076368B2/en active Active
- 2003-11-12 JP JP2005510562A patent/JP5131578B2/ja not_active Expired - Lifetime
- 2003-11-12 CN CNB200380110679XA patent/CN100528153C/zh not_active Expired - Lifetime
- 2003-11-12 KR KR1020067011405A patent/KR101008052B1/ko active IP Right Grant
- 2003-11-12 WO PCT/JP2003/014362 patent/WO2005046680A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR101008052B1 (ko) | 2011-01-13 |
US20070148217A1 (en) | 2007-06-28 |
EP1685837A1 (en) | 2006-08-02 |
EP1685837A4 (en) | 2009-03-25 |
WO2005046680A1 (ja) | 2005-05-26 |
AU2003280739A1 (en) | 2004-06-06 |
AU2003280739A8 (en) | 2005-06-06 |
JP5131578B2 (ja) | 2013-01-30 |
JPWO2005046680A1 (ja) | 2007-06-14 |
CN1878549A (zh) | 2006-12-13 |
US8076368B2 (en) | 2011-12-13 |
CA2546064C (en) | 2011-06-21 |
CA2546064A1 (en) | 2005-05-26 |
CN100528153C (zh) | 2009-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006298774A (ja) | 経皮吸収型フリーラジカル抑制製剤 | |
CA2504873C (en) | Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one | |
KR101008052B1 (ko) | 경피흡수형 뇌 보호제 | |
CA2394471C (en) | External preparation for treating pruritus | |
ZA200502356B (en) | External preparation for inhibiting keloid formation | |
KR100892813B1 (ko) | 3-메틸-1-페닐-2-피라조린-5-온 함유 경피흡수제제 | |
AU2004315561B2 (en) | External preparation for treating painful skin wound | |
KR100190450B1 (ko) | 키토산을 이용한 매트릭스형 경피흡수제제 | |
WO2019008472A1 (en) | PHARMACEUTICAL COMPOSITIONS OF LIGNOCAINE HCL | |
TW201002313A (en) | Antipruritic and analgesic medicine containing oxybuprocaine for external use | |
JPH07223949A (ja) | 消炎鎮痛外用剤 | |
JP3538367B2 (ja) | 皮膚組織障害治療・予防・改善用外用剤 | |
JPH03275624A (ja) | 新規な皮膚潰瘍治療剤 | |
KR20060130651A (ko) | 통증이 있는 피부 창상의 치료용 외용제 | |
ZA200606352B (en) | External preparation for treating painful skin wound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131219 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141204 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151208 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161205 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171211 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181211 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191211 Year of fee payment: 10 |